Asia
The agency inspected the plant from May 15 to May 24, 2017, and observed that staffers at the plant were basically gaming the quality control system.
Nanjing Legend Biotech received a very large $350M upfront payment from Janssen Biotech to partner Legend’s impressively effective CAR-T candidate.
LP Pharma raised $30M in a B round led by state-owned SDIC Fund Management.
Walgreens Boots Alliance will reduce its ownership in its China drug distribution JV with Guangzhou Pharmaceutical Co. Ltd.
Taris is developing implanted, continuous delivery devices combined with known cancer drugs for bladder disease treatment.
The biosimilar company, which has a $419M market capitalization, operates in Taiwan and Wuhan, China.
With a priority review voucher in hand, Teva is expecting the FDA to rule on its new migraine treatment fremanezumab by June.
Zhejiang Medicine has terminated its Phase III oncology trial for oral forms of prochloridine mesylate to treat AML due to a lack of efficacy.
Biotechnology major BioCon is likely to take its group entity Biocon Biologics public and is expected to raise about $500M.
Another attempt at developing a treatment for Alzheimer’s has hit a wall.
PRESS RELEASES